Previous 10 | Next 10 |
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, announced it recently completed the one-millionth Jeuveau ® redemption through its Evolus Rewards™ patient loyalty program. “We designed Evolus ...
2023-05-09 22:53:01 ET Evolus, Inc. (EOLS) Q1 2023 Earnings Conference Call May 09, 2023 04:30 PM ET Company Participants David Erickson - VP, IR David Moatazedi - President and CEO Rui Avelar - CMO and Head, Research & Development Sandra Beaver - CFO ...
2023-05-09 16:08:18 ET Evolus press release ( NASDAQ: EOLS ): Q1 GAAP EPS of -$0.26 misses by $0.01 . Revenue of $41.7M (+23.0% Y/Y) beats by $1.18M . Evolus continues to expect total net revenues for the full year 2023 to be between $180 million and $190 milli...
Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million Raises 2028 Revenue Outlook from $500 Million to $700 Million Driven by Addition of Evolysse™ Dermal Filler Line Representing a 29% CAGR F...
Portfolio of 5 Fillers in Late-Stage Development; First Approval Expected in 1H 2025 Raises 2028 Revenue Outlook from $500 Million to $700 Million Representing a 29% CAGR Highly Capital Efficient Deal Structure Funded Through $50 Million Pharmakon Tranche; Company Expects to Rem...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial mark...
2023-04-19 06:28:30 ET Summary The US neurotoxin market is rapidly growing, and Evolus has a strong position in the market, especially among younger, aesthetically-oriented consumers. The global market for non-invasive aesthetic treatments is expected to reach $150 billion by 2030...
2023-03-08 21:36:02 ET Evolus, Inc. (EOLS) Q4 2022 Earnings Conference Call March 08, 2023 04:30 PM ET Company Participants David Erickson - Vice President of Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Of...
2023-03-08 16:12:35 ET Evolus press release ( NASDAQ: EOLS ): Q4 GAAP EPS of -$0.23 misses by $0.02 . Revenue of $43.65M (+25.9% Y/Y) misses by $0.17M . Outlook: Evolus continues to expect total net revenues for full year 2023 to be between $180 million and...
Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Net Revenue of $148.6 Million, Up 49% Over 2021 Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million and Positive Non-GAAP Operating Income 1 in Q4 2023 ...
News, Short Squeeze, Breakout and More Instantly...
Launching into this growth market 1 as part of the company’s geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ: EOLS), a perf...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the following investor conference. Event: The Canaccord Genuity 44 th Annual Growth Conference Date: T...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management ...